Plumbline Life Sciences Inc

Plumbline Life Sciences Inc has a negative equity position of KRW -4,066,645,520 and a current ratio of 0.12, indicating significant liquidity constraints. The company's cash and equivalents of KRW 377,247,180 are insufficient to cover its long-term debt of KRW 1,461,498,740, further highlighting its liquidity risk. The negative operating cash flow of KRW -1,314,812,010 and free cash flow of KRW -1,357,394,520 suggest the company is not generating sufficient cash from operations to sustain its activities. The company's profitability is severely challenged, with a net loss of KRW -1,432,332,520 and an operating loss of KRW -11,841,788,200. Its return on equity of 0.3522 is positive but misleading due to the negative equity base, while its return on assets of -0.5018 indicates poor asset utilization. These metrics fall well below the typical performance of pharmaceutical companies, which are expected to maintain positive operating margins and asset returns. Plumbline Life Sciences Inc's revenue of KRW 19,200,000 is minimal, and the company does not disclose segment or geographic revenue breakdowns in the provided data. This lack of transparency makes it difficult to assess the concentration of risk in specific markets or product lines. The company's growth trajectory is negative, with a net loss and declining cash flows. The outlook for the current fiscal year is not provided, but the historical performance suggests a lack of revenue growth and increasing operational costs. The company's capital expenditures of KRW -252,000 are minimal, indicating limited investment in future capacity or innovation. The risk assessment indicates a medium liquidity risk and low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, suggesting potential challenges in meeting short-term obligations. The dilution risk is low, and no significant dilution sources are identified in the provided data. Recent events and filings are not detailed in the provided data, but the company's financial performance and liquidity position suggest a need for close monitoring of its capital structure and operational efficiency.